Merck, Inc.
🇺🇸United States
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase 3
Completed
- Conditions
- Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 882
- Registration Number
- NCT02358031
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
Phase 3
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 257
- Registration Number
- NCT02358044
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02336555
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Phase 2
Completed
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 318
- Registration Number
- NCT02335411
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
Phase 2
Completed
- Conditions
- Urothelial Cancer
- Interventions
- Biological: pembrolizumab
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 374
- Registration Number
- NCT02335424
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 443
- Registration Number
- NCT02332707
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02332720
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase 1
Recruiting
- Conditions
- MelanomaLymphomaClassical Hodgkin LymphomaSolid TumorMicrosatellite-instability-high Solid Tumor
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 370
- Registration Number
- NCT02332668
- Locations
- 🇺🇸
Call for Information (Investigational Site 0019), Aurora, Colorado, United States
🇺🇸Call for Information (Investigational Site 0026), Boston, Massachusetts, United States
🇺🇸Call for Information (Investigational Site 0031), New York, New York, United States
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02318693
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Phase 4
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Biological: Golimumab
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02318667
© Copyright 2025. All Rights Reserved by MedPath